Online citations, reference lists, and bibliographies.

Glaucoma Costs In Denmark In Treatment Naive Patients

J. Olsen, G. Berdeaux, J. Skov
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Purpose:  To describe the costs and providers of glaucoma treatment in Denmark.
This paper references
A (2007): Barbados Eye Studies Group. Nineyear incidence of open-angle glaucoma in the Barbados Eye Studies
MC Leske (2007)
Costs and effectiveness of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the United Kingdom General Practitioner
A Lafuma (2008)
10.1016/J.AJO.2007.09.013
Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study.
F. Topouzis (2008)
10.1097/00061198-199804000-00006
Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States.
G. Kobelt-Nguyen (1998)
10.1007/BF03169127
Trends in ophthalmic surgery in Ireland
V. W. Long (2005)
10.1001/archopht.1994.01090130079022
Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey.
J. Tielsch (1994)
10.1111/j.1600-0420.1996.tb00052.x
PREVALENCE OF OPEN-ANGLE GLAUCOMA IN CENTRAL SWEDEN: THE TIERP GLAUCOMA SURVEY
Curt Ekstrom (2009)
Costs of treating primary openangle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients
G Kobelt-Nguyen (1998)
Costs and effectiveness of Travatan (travoprost) versus Xalacom (Latanoprost + Timolol) as Glaucoma first-line treatments: analysis based on the United Kingdom
R De Natale (2009)
10.5301/EJO.2008.2018
Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France.
C. Baudouin (2003)
10.1177/112067210801800108
Treatment Carryover Impacts on Effectiveness of Intraocular Pressure Lowering Agents, Estimated by a Discrete Event Simulation Model
P. Denis (2008)
The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators.
The Agis Investigators (2000)
10.1016/S0161-6420(95)31054-8
Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population. The Rotterdam Study.
I. Dielemans (1995)
10.2165/0044011-200929020-00005
Cost Effectiveness of Travoprost versus a Fixed Combination of Latanoprost/Timolol in Patients with Ocular Hypertension or Glaucoma
Renato Natale (2009)
10.1016/J.OPHTHA.2004.01.029
Detection of undiagnosed glaucoma by eye health professionals.
E. Wong (2004)
10.1111/j.1442-9071.2004.00908.x
Glaucoma treatment in Australia: changing patterns of therapy 1994–2003
M. Walland (2004)
10.1177/112067210701700407
Changes in medical and surgical treatments of glaucoma between 1997 and 2003 in France.
Kenigsberg Pa (2007)
Costs and effectiveness of brimoni - dine versus brinzolamide in everyday glaucoma care : an analysis conducted on the United Kingdom General Practitioner ResearchDatabase
A Lafuma (2011)
10.1111/j.1755-3768.2009.01532.x
The need and total cost of Finnish eyecare services: a simulation model for 2005–2040
A. Tuulonen (2009)
Open-angle glaucoma.
James S. Distelhorst (2003)
10.1185/030079908X292038
Costs and persistence of carbonic anhydrase inhibitor versus alpha‑2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK‑GPRD database*
A. Lafuma (2008)
Family history and risk of primary openangle glaucoma
JM Tielsch (1994)
10.1177/112067210301304S06
Changes in Medical and Surgical Treatments of Glaucoma between 1997 and 2000 in France
C. Baudouin (2003)
10.1016/S0161-6420(02)01040-0
Five-year incidence of open-angle glaucoma: the visual impairment project.
B. Mukesh (2002)
Costs and effectiveness of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma
P Denis (2008)
Economics of surgery worldwide
DR Strutton (2004)
10.1185/030079908X292038
Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database.
A. Lafuma (2008)
10.1136/bjo.2005.080986
The economic impact and cost of visual impairment in Australia
H. Taylor (2006)
10.1136/bjo.86.5.551
The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care
D. Bateman (2002)
10.1016/S0161-6420(96)30511-3
Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population. The Rotterdam Study.
I. Dielemans (1996)
10.2147/OPTH.S2832
Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database
P. Denis (2008)
10.5301/EJO.2008.3211
Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.
J. Rouland (2005)
10.3111/13696990902728729
Modelling the lifetime economic consequences of glaucoma in France
Jean Philippe Nordmann (2009)
10.2147/OPTH.S7113
First-year treatment costs among new initiators of topical prostaglandin analogs
J. Schmier (2009)
10.1016/J.OPHTHA.2005.04.018
Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study.
S. de Voogd (2005)
10.1097/IJG.0b013e3181e0791c
Efficiency of Glaucoma Drug Regulation in 5 European Countries: A 1995-2006 Longitudinal Prescription Analysis
R. de Natale (2011)
Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first line treatment of glaucoma: analysis
A Lafuma (2007)
10.1001/ARCHOPHT.120.6.701
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
M. Kass (2002)
10.1016/B978-0-7020-5193-7.00003-0
Economics of Glaucoma Care
Lee Kiang (2015)
10.1016/S0002-9394(00)00538-9
The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration
F. Ederer (2000)
10.1097/00061198-200408000-00005
Medical Predictive Factors of Glaucoma Treatment Costs
P. Denis (2004)
10.1017/S0266462399015299
Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom.
G. Kobelt (1999)
10.2147/OPTH.S10486
First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
J. Schmier (2010)
10.1038/sj.eye.6702593
A review of glaucoma treatment in Scotland 1994–2004
S. Macleod (2008)
10.3111/13696990802211107
Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database
A. Lafuma (2008)
10.1097/01.ijg.0000133385.74502.29
Prevalence of Primary Open-Angle Glaucoma in a Spanish Population: The Segovia Study
A. Antón (2004)
Openangle glaucoma
JS Distelhorst (2003)
10.1016/J.OPHTHA.2006.08.051
Nine-year incidence of open-angle glaucoma in the Barbados Eye Studies.
M. C. Leske (2007)
10.1111/J.1600-0420.2007.00980.X
Incidence and prevalence of pseudoexfoliations and open-angle glaucoma in northern Sweden: II. Results after 21 years of follow-up.
S. Åström (2007)
Family history and risk of primary open - angle glaucoma . The Baltimore Eye Sur
F Topouzis
10.1097/01.ijg.0000159121.11371.5f
The Impact of a Nationwide Introduction of New Drugs and a Treatment Protocol for Glaucoma on the Number of Glaucoma Surgeries
Rikkert van der Valk (2005)
10.1185/030079907X242836
Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database*
A. Lafuma (2007)
Efficiency of glaucoma drug regulation in five European countries
R De Natale (2011)
The impact of a nation
CA (2005)
10.1185/03007990802111068
Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries*
J. Thygesen (2008)
10.1097/01.ijg.0000184834.93535.0b
Clinical Outcomes of Glaucoma Treatments Over a Patient Lifetime: A Markov Model
J. P. Nordmann (2005)
10.2147/OPTH.S16888
Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
A. Lafuma (2011)
10.1167/IOVS.03-0077
Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project.
Anhchuong Le (2003)
10.1001/ARCHOPHT.124.12.1754
The economic burden of major adult visual disorders in the United States.
D. Rein (2006)
10.1136/BJO.2005.076117
The rising cost of glaucoma drugs in Ireland 1996–2003
F. A. Knox (2006)
10.2165/00019053-200624020-00007
Evaluation of Non-Medical Costs Associated with Visual Impairment in Four European Countries
A. Lafuma (2012)
10.1111/J.1600-0420.1996.TB00052.X
Prevalence of open-angle glaucoma in central Sweden. The Tierp Glaucoma Survey.
C. Ekström (1996)
Treatment persistence and costeffectiveness of latanoprost ⁄ latanoprosttimolol, bimatoprost ⁄ bimatoprost-timolol, and travoprost ⁄ travoprost-timolol in glau
A Lafuma (2011)
10.1111/j.1755-3768.2008.01244.x
Incidence of open‐angle glaucoma in central Sweden
C. Ekström (2008)
10.1001/ARCHOPHT.124.10.1472
Effect of medical therapy on glaucoma filtration surgery rates in Ontario.
R. Rachmiel (2006)
10.1016/0002-9394(85)90001-7
Race and primary open-angle glaucoma.
M. Martin (1985)
Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population
I Dielemans (1995)
Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population
I Dielemans (1996)
10.1097/00061198-200406000-00008
Trends in Glaucoma Surgery before and after the Introduction of New Topical Glaucoma Pharmacotherapies
D. Strutton (2004)
10.1111/J.1600-0420.2007.00947.X
Cost effectiveness and cost utility of an organized screening programme for glaucoma.
Hanna Vaahtoranta-Lehtonen (2007)



This paper is referenced by
10.17925/usor.2019.12.2.78
Allocating Resources for Glaucoma Care—A Review
Nkiru N. Kizor-Akaraiwe (2019)
10.1097/IJG.0000000000001462
Health Economic Analysis in Glaucoma
In-hae Park (2020)
10.22608/APO.2018392
The Current Status of Glaucoma and Glaucoma Care in Sub‐Saharan Africa
F. Kyari (2018)
10.1007/s10792-013-9823-6
Topical glaucoma therapy cost in Mexico
Gabriel S. Lazcano-Gomez (2013)
10.1111/aos.12328
The long term effectiveness and cost‐effectiveness of initiating treatment for ocular hypertension
Aukje Gestel (2014)
10.1007/s40123-018-0131-0
Systematic Literature Review of Clinical and Economic Outcomes of Micro-Invasive Glaucoma Surgery (MIGS) in Primary Open-Angle Glaucoma
P. Agrawal (2018)
A socioeconomic evaluation of early-stage and moderate glaucoma patients
Miglė Lindžiūtė (2019)
10.1155/2015/243401
Trends in Glaucoma Medication Expenditures under Universal Health Coverage: A National Population-Based Longitudinal Survey in Taiwan
Shin-Lin Chiu (2015)
10.17925/EOR.2011.05.02.116
Adverse Effects, Adherence and Cost–Benefits in Glaucoma Treatment
Philippe Denis (2011)
10.1371/journal.pone.0226015
Factors influencing harmonized health data collection, sharing and linkage in Denmark and Switzerland: A systematic review
Lester Darryl Geneviève (2019)
10.1371/journal.pone.0132048
The Prevalence and Incidence of Glaucoma in Denmark in a Fifteen Year Period: A Nationwide Study
M. Kolko (2015)
10.2147/OPTH.S190754
Comparing the long-term impact on health care resources utilization and costs due to various single-piece acrylic monofocal intraocular lens implantation during cataract surgery: a cost-consequence analysis for the United Kingdom, Italy, and Denmark
Mukesh Dhariwal (2019)
10.1111/aos.12088
Challenges of glaucoma care – high volume, high quality, low cost
A. Tuulonen (2013)
Semantic Scholar Logo Some data provided by SemanticScholar